My laboratory explores the factors underlying the hormone-dependence of breast and prostate cancers. I am recognized for three seminal discoveries, including the role of p160 co-activators in steroid receptor action, the dynamic nature of co-regulator function, and the predominance of steroid receptors as enhancer-rather than promoter-binding factors.

I am today director of the Center for Functional Cancer Epigenetics at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. I earned my M.D. from Johns Hopkins, and trained in internal medicine at the Brigham and Women’s Hospital. Following a fellowship in medical oncology at Dana-Farber and postdoctoral research at MIT, I joined the staff of Dana-Farber and the faculty of Harvard Medical School.